Docosahexaenoic Acid Inhibits Osteoclastogenesis via FFAR4-Mediated Regulation of Inflammatory Cytokines
Molecules · 2025
DOI: 10.3390/molecules30153180 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, 2025. Verfasst von Jinghan Ma und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Orthodontics and Dentofacial Orthopedics, Tohoku University Graduate School of Dentistry, 4-1, Seiryo-machi, Aoba-ku, Sendai 980-8575, Mi…. Hauptthemen laut MEDLINE: Docosahexaenoic Acids, Receptors, G-Protein-Coupled, Osteogenesis, Cytokines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Osteoclastogenesis—the activation and differentiation of osteoclasts—is one of the pivotal processes of bone remodeling and is regulated by RANKL/RANK signaling, the decoy function of osteoprotegerin (OPG), and a cascade of pro- and anti-inflammatory cytokines. The disruption of this balance leads to pathological bone loss in diseases such as osteoporosis and rheumatoid arthritis. FFAR4 (Free Fatty Acid Receptor 4), a G protein-coupled receptor for long-chain omega-3 fatty acids, has been confirmed as a key mediator of metabolic and anti-inflammatory effects. This review focuses on how FFAR4 acts as the selective receptor for the omega-3 fatty acid docosahexaenoic acid (DHA). It activates two divergent signaling pathways. The Gαq-dependent cascade facilitates intracellular calcium mobilization and ERK1/2 activation. Meanwhile, β-arrestin-2 recruitment inhibits NF-κB. These collective actions reshape the cytokine environment. In macrophages, DHA–FFAR4 signaling lowers the levels of TNF-α, interleukin-6 (IL-6), and IL-1β while increasing IL-10 secretion. Consequently, the activation of NFATc1 and NF-κB p65 is profoundly suppressed under TNF-α or RANKL stimulation. Additionally, DHA modulates the RANKL/OPG axis in osteoblastic cells by suppressing RANKL expression, thereby reducing osteoclast differentiation in an inflammatory mouse model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Orthodontics and Dentofacial Orthopedics, Tohoku University Graduate School of Dentistry, 4-1, Seiryo-machi, Aoba-ku, Sendai 980-8575, Miyagi, Japan.
- Frontier Research Institute for Interdisciplinary Sciences, Tohoku University, Sendai 980-8575, Miyagi, Japan.
- Division of Advanced Dental Science and Technology, Graduate School of Biomedical Engineering, Tohoku University, 6-6-12, Aramaki Aza Aoba Aoba-ku, Sendai 980-8579, Miyagi, Japan.
ORCID-Profile: Hideki Kitaura, Ziqiu Fan, Angyi Lin
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Ma, J., Kitaura, H., Ohori, F., Marahleh, A., Fan, Z., Lin, A., Narita, K., Murakami, K., & Kanetaka, H. (2025). Docosahexaenoic Acid Inhibits Osteoclastogenesis via FFAR4-Mediated Regulation of Inflammatory Cytokines. Molecules. https://doi.org/10.3390/molecules30153180
Vancouver
Ma J, Kitaura H, Ohori F, Marahleh A, Fan Z, Lin A, et al. Docosahexaenoic Acid Inhibits Osteoclastogenesis via FFAR4-Mediated Regulation of Inflammatory Cytokines. Molecules. 2025. doi:10.3390/molecules30153180
BibTeX
@article{Ma2025,
author = {Ma, Jinghan and Kitaura, Hideki and Ohori, Fumitoshi and Marahleh, Aseel and Fan, Ziqiu and Lin, Angyi and Narita, Kohei and Murakami, Kou and Kanetaka, Hiroyasu},
title = {Docosahexaenoic Acid Inhibits Osteoclastogenesis via FFAR4-Mediated Regulation of Inflammatory Cytokines},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30153180}
}
EUVIMED